252 related articles for article (PubMed ID: 34997219)
1. Pathophysiological role of ion channels and transporters in HER2-positive breast cancer.
Zhou Z; Zhang C; Ma Z; Wang H; Tuo B; Cheng X; Liu X; Li T
Cancer Gene Ther; 2022 Aug; 29(8-9):1097-1104. PubMed ID: 34997219
[TBL] [Abstract][Full Text] [Related]
2. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant therapeutic approaches of HER2-positive breast cancer with a focus on neratinib maleate.
Kotecki N; Gombos A; Awada A
Expert Rev Anticancer Ther; 2019 Jun; 19(6):447-454. PubMed ID: 31082272
[No Abstract] [Full Text] [Related]
4. Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors.
Dieci MV; Miglietta F; Griguolo G; Guarneri V
Cancer Treat Rev; 2020 Aug; 88():102064. PubMed ID: 32622272
[TBL] [Abstract][Full Text] [Related]
5. NCAPG confers trastuzumab resistance via activating SRC/STAT3 signaling pathway in HER2-positive breast cancer.
Jiang L; Ren L; Chen H; Pan J; Zhang Z; Kuang X; Chen X; Bao W; Lin C; Zhou Z; Huang D; Yang J; Huang H; Wang L; Hou N; Song L
Cell Death Dis; 2020 Jul; 11(7):547. PubMed ID: 32683421
[TBL] [Abstract][Full Text] [Related]
6. Evolving standards of care and new challenges in the management of HER2-positive breast cancer.
Choong GM; Cullen GD; O'Sullivan CC
CA Cancer J Clin; 2020 Sep; 70(5):355-374. PubMed ID: 32813307
[TBL] [Abstract][Full Text] [Related]
7. Identification of the key pathways and genes involved in HER2-positive breast cancer with brain metastasis.
Lu X; Gao C; Liu C; Zhuang J; Su P; Li H; Wang X; Sun C
Pathol Res Pract; 2019 Aug; 215(8):152475. PubMed ID: 31178227
[TBL] [Abstract][Full Text] [Related]
8. First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?
Fabi A; Malaguti P; Vari S; Cognetti F
J Exp Clin Cancer Res; 2016 Jun; 35():104. PubMed ID: 27357210
[TBL] [Abstract][Full Text] [Related]
9. High cell-surface density of HER2 deforms cell membranes.
Chung I; Reichelt M; Shao L; Akita RW; Koeppen H; Rangell L; Schaefer G; Mellman I; Sliwkowski MX
Nat Commun; 2016 Sep; 7():12742. PubMed ID: 27599456
[TBL] [Abstract][Full Text] [Related]
10. The expression and prognostic role of EBP1 and relationship with AR in HER2+ breast cancer.
Liu J; Xu C; Xu D; Cao L; Xue H; Meng Q; Niu Y
Virchows Arch; 2020 Aug; 477(2):279-289. PubMed ID: 32086588
[TBL] [Abstract][Full Text] [Related]
11. Protein Corona Gold Nanoparticles Fingerprinting Reveals a Profile of Blood Coagulation Proteins in the Serum of HER2-Overexpressing Breast Cancer Patients.
Chantada-Vázquez MDP; Castro López A; García-Vence M; Acea-Nebril B; Bravo SB; Núñez C
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182810
[TBL] [Abstract][Full Text] [Related]
12. HER2-positive circulating tumor cells in breast cancer.
Ignatiadis M; Rothé F; Chaboteaux C; Durbecq V; Rouas G; Criscitiello C; Metallo J; Kheddoumi N; Singhal SK; Michiels S; Veys I; Rossari J; Larsimont D; Carly B; Pestrin M; Bessi S; Buxant F; Liebens F; Piccart M; Sotiriou C
PLoS One; 2011 Jan; 6(1):e15624. PubMed ID: 21264346
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors and outcome of HER2+ breast cancer with CNS metastases.
Masci G; Agostinetto E; Giordano L; Bottai G; Torrisi R; Losurdo A; De Sanctis R; Navarria P; Scorsetti M; Zuradelli M; de Rose F; Bello L; Santoro A
Future Oncol; 2020 Mar; 16(7):269-279. PubMed ID: 32043375
[No Abstract] [Full Text] [Related]
14. The influence of breast cancer subtypes on the response to anthracycline neoadjuvant chemotherapy in locally advanced breast cancer patients.
Stamatovic L; Susnjar S; Gavrilovic D; Minic I; Ursulovic T; Dzodic R
J BUON; 2018; 23(5):1273-1280. PubMed ID: 30570847
[TBL] [Abstract][Full Text] [Related]
15. The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.
Dittrich A; Gautrey H; Browell D; Tyson-Capper A
J Mammary Gland Biol Neoplasia; 2014 Dec; 19(3-4):253-70. PubMed ID: 25544707
[TBL] [Abstract][Full Text] [Related]
16. Triple-negative and HER2-overexpressing breast cancers exhibit an elevated risk and an earlier occurrence of cerebral metastases.
Heitz F; Harter P; Lueck HJ; Fissler-Eckhoff A; Lorenz-Salehi F; Scheil-Bertram S; Traut A; du Bois A
Eur J Cancer; 2009 Nov; 45(16):2792-8. PubMed ID: 19643597
[TBL] [Abstract][Full Text] [Related]
17. Functional SNP in stem of mir-146a affects Her2 status and breast cancer survival.
Meshkat M; Tanha HM; Naeini MM; Ghaedi K; Sanati MH; Meshkat M; Bagheri F
Cancer Biomark; 2016 Jul; 17(2):213-22. PubMed ID: 27434289
[TBL] [Abstract][Full Text] [Related]
18. De novo resistance biomarkers to anti-HER2 therapies in HER2-positive breast cancer.
Madrid-Paredes A; Cañadas-Garre M; Sánchez-Pozo A; Calleja-Hernández MÁ
Pharmacogenomics; 2015; 16(12):1411-26. PubMed ID: 26257318
[TBL] [Abstract][Full Text] [Related]
19. HER2-family signalling mechanisms, clinical implications and targeting in breast cancer.
Elster N; Collins DM; Toomey S; Crown J; Eustace AJ; Hennessy BT
Breast Cancer Res Treat; 2015 Jan; 149(1):5-15. PubMed ID: 25542271
[TBL] [Abstract][Full Text] [Related]
20. Truncated HER2: implications for HER2-targeted therapeutics.
Zagozdzon R; Gallagher WM; Crown J
Drug Discov Today; 2011 Sep; 16(17-18):810-6. PubMed ID: 21704182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]